



Modular synthesis of diphospholipid oligosaccharide fragments of the bacterial cell wall and their use to study the mechanism of moenomycin and other antibiotics

Christian M. Gampe^a, Hirokazu Tsukamoto^a, Tsung-Shing Andrew Wang^a, Suzanne Walker^{b,*}, Daniel Kahne^{a,*}

^a Harvard University, Department of Chemistry and Chemical Biology, 12 Oxford Street, Cambridge, MA 02138, USA

^b Harvard Medical School, Department of Microbiology and Molecular Genetics, Boston, MA 02115, USA

ARTICLE INFO

Article history:

Received 23 August 2011

Received in revised form 21 September 2011

Accepted 23 September 2011

Available online 29 September 2011

Keywords:

Lipid IV

Moenomycin

Peptidoglycan

Transglycosylation

Carbohydrate synthesis

ABSTRACT

We present a flexible, modular route to GlcNAc–MurNAc-oligosaccharides that can be readily converted into peptidoglycan (PG) fragments to serve as reagents for the study of bacterial enzymes that are targets for antibiotics. Demonstrating the utility of these synthetic PG substrates, we show that the tetrasaccharide substrate lipid IV (**3**), but not the disaccharide substrate lipid II (**2**), significantly increases the concentration of moenomycin A required to inhibit a prototypical PG-glycosyltransferase (PGT). These results imply that lipid IV and moenomycin A bind to the same site on the enzyme. We also show the moenomycin A inhibits the formation of elongated polysaccharide product but does not affect length distribution. We conclude that moenomycin A blocks PG-strand initiation rather than elongation or chain termination. Synthetic access to diphospholipid oligosaccharides will enable further studies of bacterial cell wall synthesis with the long-term goal of identifying novel antibiotics.

© 2011 Elsevier Ltd. All rights reserved.

1. Introduction

Bacteria have evolved a cell wall that protects the cell membrane from hostile environments and allows the cells to withstand varying osmotic pressures.¹ The supportive structure of the cell wall is peptidoglycan (PG), consisting of polysaccharide threads of alternating *N*-acetylglucosamine (GlcNAc) and *N*-acetylmuramic acid (MurNAc) units.² These polysaccharides are cross-linked through peptide side chains appended to the MurNAc units to form a stable polymeric mesh. Many highly effective antibacterial drugs disrupt the formation of the cell wall, which ultimately results in cell death. It is important to better understand cell wall synthesis in order to develop new therapies for bacterial infections.³

Work over the past several decades has shed light on the biosynthesis of PG. In the final stages of biosynthesis lipid II (**2**, Fig. 1) is polymerized by peptidoglycan glycosyl transferase (PGT) and the resulting polysaccharide strands are then linked by transpeptidases (TPs).² Many different classes of natural product

antibiotics that inhibit strand polymerization and cross-linking have been identified (e.g., Scheme 1). These antibiotics function by three major type of mechanisms: (1) They bind to PGT substrates, such as **2**, sequestering them so they are unavailable for PG-strand synthesis and cross-linking (e.g., vancomycin⁴ and ramoplanin⁵); (2) They acylate TP-domains, inactivating them so that they are incapable of strand cross-linking (e.g., the beta-lactams);⁶ or (3) they bind to PGT domains, preventing PG strand formation (e.g., moenomycin A (**1**), Fig. 1).⁷ Antibiotics having the first or second mechanism of action have been highly effective in the clinic but there are no approved drugs with the third mechanism.⁸

The natural product moenomycin A (**1**), which binds to PGTs, has potent antibacterial activity against Gram-positive pathogens and has been used as a growth promoter in animals for decades without engendering resistance.⁹ Its use in humans has been prevented by unfavorable pharmacokinetic properties (e.g., a long half-life and low oral bioavailability)^{8d} but it can serve as a blueprint for the development of other PGT inhibitors. Hence, a detailed understanding of how **1** inhibits PGTs is important for exploiting these crucial enzymes as antibiotic targets.

A major impediment to study antibiotics that inhibit PGTs has been the lack of access to substrates used by these enzymes. PGTs catalyze the transformation of lipid II (**2**) into a polymer. In

* Corresponding authors. Tel.: +1 617 496 0208; fax: +1 617 496 0215 (D.K.); tel.: +1 617 432 5488; fax: +1 617 496 0215 (S.W.); e-mail addresses: suzanne_walker@hms.harvard.edu (S. Walker), kahne@chemistry.harvard.edu (D. Kahne).





Fig. 1. Molecular structures of moenomycin A (1), lipid II (2), and lipid IV (3).



Scheme 1. The final stages of peptidoglycan biosynthesis involve polymerization of lipid II to make oligosaccharide chains followed by cross-linking via transpeptidation. This sequence is often performed by bifunctional enzymes containing distinct glycosyl transferase (GT) and transpeptidase (TP) domains (depicted in gray). Peptidoglycan synthesis can be disrupted at different steps by various antibiotics.

the first round of synthesis, two units of lipid II are coupled. In subsequent rounds of synthesis, lipid II adds in a processive manner to the elongating glycan strand. In order to dissect the reaction, it is necessary to have both disaccharide and oligosaccharide substrates available to discriminate between the glycosyl acceptor and the glycosyl donor sites of the enzyme. For over a decade we, and others, have been developing methods to obtain PGT substrates as well as assays using these substrates to probe the mechanisms and inhibition of PG biosynthetic enzymes.¹⁰ Here we report a modular synthesis of polysaccharides that serve as specific mimics of the glycosyl donor strand. Furthermore, we used these substrates to learn more about the mode of action of moenomycin A.

2. Results and discussion

An efficient synthesis of lipid IV (3) and its higher homologs, i.e., lipid VI, VIII etc., must address a number of challenges associated with these intriguing, structurally complex, primary metabolites. First and foremost we had to fundamentally change our previously described synthetic strategy (Scheme 2).^{10l,m} Whereas the previous route was specifically tailored to obtain 3, we now required a strategy that would easily allow access to a variety of


polysaccharides of different chain lengths, comprising $n \times \text{GlcNAc} - \text{MurNAc}$ -units (cf. 10). We envisioned the use of a disaccharide building block 4 that could be converted into both a disaccharide donor (5) and acceptor (6), which would then be coupled to obtain tetrasaccharide 7. A similar sequence of differentiation and coupling would give access to octasaccharide 10 and higher polysaccharides at will. Additionally, we required a large amount of *Z,Z,Z,Z,E,E*-heptaprenyl phosphate 12 for use as an acceptor substrate. We thus sought a scalable, stereoselective route to the heptaprenyl alcohol starting from the readily available *E,E*-farnesol. Since current methods for the preparation of pyrophosphates (13) are inefficient, an effective protocol for the formation of pyrophosphates by condensation of two monophosphates needed to be established.

2.1. Synthesis of *Z,Z,Z,Z,E,E*-heptaprenyl alcohol


For the synthesis of heptaprenyl alcohol 21 we devised a synthetic route that relied on the finding of Casey and co-workers that β-keto esters can be stereoselectively converted into their diethylphosphoryl enol ethers.¹¹ These, in turn, react stereospecifically

in a substitution reaction with methylcuprates.¹² Thus, *E,E*-farnesol (14) was converted into β-keto ester 15 in 84% yield (over two steps). Execution of Casey's and Weiler's protocols followed by reduction of the ester with DIBAL-H provided *E,E,Z*-tetraprenyl alcohol 17 as the only stereoisomer observed and yields ranged from 30 to 50% over five steps (Scheme 3).^{11,12}

Upon iteration of this procedure with 17 we noted, however, that the *Z/E* ratio eroded in the third cycle. The desired hexaprenyl alcohol 19 was obtained in a 7/3 mixture along with its double bond isomer. Purification by chromatography proved unsuccessful and we were forced to optimize the reaction conditions with regard to stereospecificity of the substitution of the phosphate by a methyl group. To this end we switched from a diethyl phosphate to a diphenyl phosphate leaving group and were able to derive enol ether 18 in 60% yield over three steps. Gratifyingly, we found that 18 participated in a highly efficient and stereospecific cross coupling reaction with MeMgCl using Fe(acac)₃ as catalyst.¹³ After DIBAL-H reduction we obtained 19 in 75% (over two steps). Moreover, we found that the iron-catalyzed cross coupling retained its high stereospecificity upon iteration of the sequence to provide the desired heptaprenyl alcohol 21 in an average yield of 7% from farnesol. With this procedure in hand we obtained more than 2 g of 21, and we next turned our attention to the development of an efficient coupling procedure for the formation of pyrophosphates.



Scheme 2. Disaccharide **4**, equipped with a suitable C4–OH group (red dot) and an anomeric protecting group (black dot), gets converted into both a disaccharide donor (**5**) and acceptor (**6**). Coupling of **5** and **6** yields tetrasaccharide **7** that can be converted into octasaccharide **10** in a similar sequence via donor **8** and acceptor **9**. Repetition of this sequence followed by coupling to **12** allows access to diphospholipid oligosaccharides **13** with different length of the oligosaccharide.




Scheme 3. Reagents and conditions: (a) PBr_3 (0.37 equiv), Et_2O , -30°C to rt, 96%; (b) ethyl acetoacetate (2 equiv), NaH (2.2 equiv), BuLi (2.1 equiv), THF, 0°C , 87%; (c) $\text{ClPO}(\text{OEt})_2$ (1.1 equiv), NEt_3 (1.1 equiv), DMAP (0.1 equiv), DMPU, 0°C , 69%; (d) CuI (3 equiv), MeLi (3 equiv), MeMgCl (5 equiv) THF; (e) DIBAL-H (2.2 equiv), PhMe, 66% over two steps; (f) PBr_3 (0.37 equiv), Et_2O , -30°C to rt; (g) ethyl acetoacetate (2 equiv), NaH (2.2 equiv), BuLi (2.1 equiv), THF, 0°C , 70% (two steps); (h) $\text{ClPO}(\text{OPh})_2$ (2 equiv), NEt_3 (2 equiv), DMAP (0.2 equiv), DMPU, 0°C , 86%; (i) MeMgCl (3 equiv), $\text{Fe}(\text{acac})_3$ (0.05 equiv), THF/NMP=20/1; (j) DIBAL-H (2.2 equiv), PhMe, 75% (two steps); (k) see f–j, 45–60% yield over five steps.

2.2. N-Methylimidazolium chloride as an effective catalyst for pyrophosphate formation

We recently reported the identification of *N*-methyl imidazolium chloride as a catalyst for pyrophosphate formation by condensation of two phosphates (**Scheme 4**).¹⁴ This catalyst is superior to the commonly employed tetrazole with respect to activity, cost, and safety. Using this catalyst we established a synthesis of lipid I. Sugar phosphate **22** was first converted to phosphorimidazolidine **23**, which was coupled with heptaprenyl phosphate **21** in 12 h. After

removal of the protecting groups, pyrophosphate **24** was obtained in acceptable yields (54%) and was subsequently transformed into lipid I, showcasing the utility of this protocol for the synthesis of lipid pyrophosphate saccharides.




Scheme 4. Reagents and conditions: (a) CDI, DMF then MeOH; (b) *N*-Methylimidazole·HCl (4 equiv), DMF/THF 1/1, rt, 12 h; (c) 1 M LiOH·H₂O, THF/MeOH/H₂O (3:1:1), 54%.

2.3. Modular synthesis of polysaccharides

The modular synthesis of the polysaccharide part of the lipid pyrophosphate sugars started with readily available glucosamine derivative **25** and took advantage of the bifunctionality of its thioether group, the phthalimide group, as well as a benzylic acetal at C4 and C6 (**Scheme 5**).¹⁵ Thiophenol is a powerful protecting group of the anomeric position but can easily be converted into its sulfide,¹⁶ which in turn is activated with TiCl_4 under mild conditions (-78°C) to provide a superb glycosyl donor.¹⁷ Phthalimides at C2 are known to sterically shield the C3 position, obviating an additional protecting group for the C3 hydroxy group.¹⁸ Phthalimide groups also provide anchimeric assistance to allow glycosylation to occur with high β -selectivity. Finally, a number of procedures have been put forth for the reduction of a C4/C6 acetal, which allows selective liberation of the C4 group.¹⁹


Glucosamine **25** was thus converted into both glycosyl donor **26**, by protection of C3 and oxidation of the thioether, and glycosyl



Scheme 5. Reagents and conditions: (a) BnBr (1.1 equiv), NaH (1.2 equiv), Bu₄NI (0.1 equiv), DMF, rt, 70%; (b) mCPBA (1 equiv), CH₂Cl₂, –78 °C to rt, 88%; (c) HSiEt₃ (5 equiv), TFA (5 equiv), CH₂Cl₂, 0 °C, 93%; (d) **27** (1.5 equiv), ADMB (5 equiv), DTBMP (5 equiv), Tf₂O (1 equiv), CH₂Cl₂, MS 4 Å, 58%; (e) mCPBA (1.1 equiv), CH₂Cl₂, 77%; (f) HSiEt₃ (12 equiv), BF₃·OEt₂ (2 equiv), CH₂Cl₂, 70%; (g) **29** (1.25 equiv), ADMB (6.25 equiv), DTBMP (3.75 equiv), Tf₂O (1.25 equiv), CH₂Cl₂, MS 4 Å, 55%. Abbreviations: ADMB=4-allyl-1,2-dimethoxybenzene, DTBMP=2,6-di-*tert*-butyl-4-methylpyridine.

acceptor **27** by reduction of the acetal using triethylsilane and TFA. These two building blocks were then coupled under conditions previously developed in our group to give β-1,4-disaccharide **28** in 57% yield.¹⁷ To suppress formation of a trisaccharide (at C3), it proved beneficial to employ an excess of the glycosyl acceptor, which could be reisolated after the reaction. Disaccharide **28** was then subjected to a similar sequence to obtain glycosyl acceptor **30** (HSiEt₃, BF₃·OEt₂, 70%) and glycosyl donor **29** (77%). These disaccharides were again subjected to Tf₂O-induced glycosylation and tetrasaccharide **31** was obtained in 55% yield. In this case excess disaccharide donor proved beneficial and residual acceptor **30** could be reisolated (20%). The regioselectivity of the reaction to give the C4-glycosylated product was verified by acylation of the C3–OH group, which leads to a significant ¹H NMR downfield shift of the proton at C3 (ca. 5.7 ppm).²⁰ Furthermore, we found that the carbon atom that bears the glycosyl substituent experiences a ¹³C NMR downfield shift, which allows facile structure determination (C3 from ca. 70 ppm to 80 ppm; C4 from ca. 75 ppm to ca. 85 ppm, as determined by HSQC). We obtained precursors to lipid II (**28**) and lipid IV (**31**) as required for the studies reported below but this synthetic sequence could be further extended to obtain similarly substituted hexa-, octa-, deca-, etc. saccharides.

To show the utility of this approach we converted **31** into heptaprenyl-lipid IV (**3b**) (Scheme 6). To this end we installed the *N*-acetates by aminolysis of the phthalimide with ethylenediamine, followed by acylation of the free amine. The C3-lactic acid substituent was subsequently installed by S_N2-reaction with *S*-(–)-2-bromopropionic acid followed by methylation of the carboxylate with TMS-diazomethane to obtain **33** in 53% yield from **31**. Substrate **33** intercepted a late stage in our previously published synthesis and can be converted into lipid IV.^{10m}



Scheme 6. Reagents and conditions: (a) ethylenediamine, EtOH/MeCN/THF, 60 °C, 48 h; then: Ac₂O, MeOH/H₂O, 70%; (b) NaH, DMF, *S*-2-bromopropionic acid, then: TMSCHN₂, MeOH, PhH; 75%; (c) see Ref. 10m.

2.4. Use of synthetic PG substrates to study the mechanism of moenomycin A inhibition

We have previously reported that inhibition of the prototypical PGT, *Escherichia coli* PBP1a, by moenomycin A cannot be overcome by increasing the concentration of lipid II.^{10h} The complexity of the enzymatic reaction, which involves substrate differentiation and processive elongation, makes it challenging to interpret this result. Therefore, we have revisited the question of how moenomycin A inhibits PGT using a different approach that employs both lipid II and a lipid IV substrate containing a blocked non-reducing end (Gal-lipid IV).²¹ The concentration of moenomycin A required to inhibit by 50% (IC₅₀) the polymerization of lipid II by *E. coli* PBP1a (20 nM) was found to be 9.2 nM (Fig. 2); or approximately 1/2 the enzyme concentration. This IC₅₀ reflects the high affinity of moenomycin A for the enzyme. The addition of 1.4 μM Gal-lipid IV, which functions only as a glycosyl donor, shifts the IC₅₀ of moenomycin A fivefold.²² The shift implies that Gal-lipid IV and moenomycin A compete for binding to the same site on the enzyme. It has previously been suggested that moenomycin A is a mimetic of the elongating glycan strand but the results reported here provide the first kinetic evidence that the inhibitor and the elongating substrate occupy the same site.²³




Fig. 2. Dose-response curves of the moenomycin A inhibition of peptidoglycan formation. Solutions of *E. coli* PBP1a (20 nM) were incubated with moenomycin A in different concentrations and then treated with ¹⁴C-lipid II (4 μM). Distribution of lipid II/polysaccharide was determined by scintillation count after paper chromatography of the product solution. Blue curve: no Gal-lipid IV added; red curve: PBP1a was pre-treated with Gal-lipid IV (1.36 μM).

We next examined whether moenomycin A has any effect on the length distribution of products formed by the PGT catalyzed polymerization of lipid II. *E. coli* PBP1a was incubated with lipid II in the presence of increasing concentrations of moenomycin A and the products were analyzed by SDS-PAGE (Fig. 3).^{10h,24} PG-polymers could not be detected at moenomycin concentrations equal to or exceeding the enzyme concentration even at extended reaction

times. At moenomycin concentrations below the enzyme concentration, products were detected but the length distribution appeared similar regardless of the inhibitor concentration. Since the resolution of the page assay is limited for very long products, we repeated the experiments with a different PGT that was previously shown to produce much shorter products.^{10l,m} As before, products were not detected at equimolar enzyme:moenomycin concentrations. Products formed at lower moenomycin concentrations, but the length distribution did not vary significantly as a function of concentration. These results imply a mechanism for inhibition in which moenomycin A blocks chain initiation rather than elongation or termination since effects on the latter stages of the enzymatic reaction would alter product length (Scheme 7).





Fig. 3. SDS-PAGE of enzymatic ¹⁴C-lipid II-polymerization reactions (8 μM) with varying amounts of moenomycin A (MmA) present. Red lines mark equimolar ratio of enzyme to moenomycin A. In reactions with $c(\text{MmA}) \geq c(\text{PBP})$ no polymerization of lipid II is observed. If $c(\text{MmA}) < c(\text{PBP})$, polysaccharide is produced. Note that the length distribution of polysaccharides formed varies with the enzyme employed but is not influenced by moenomycin A.



Scheme 7. Model for lipid II-polymerization by peptidoglycan glycosyltransferases (PGTs) and their inhibition by moenomycin A (MmA). Moenomycin A blocks initiation of the polymerization of lipid II by binding to the donor site (D) of the PGT.

3. Conclusion

We report a modular synthesis of diphospholipid oligosaccharides using a bifunctional disaccharide building block. Along with our improved synthesis of pyrophosphates and of heptaprenyl alcohol, this synthetic sequence provides access to higher-order

oligosaccharide cell wall fragments. We have used these PG fragments, containing diphosphate activated reducing termini, to evaluate the mechanism of action of moenomycin A. We have provided the first kinetic evidence that moenomycin A occupies the same binding site as the elongating PG strand. Since we have previously shown that PG strands elongate by addition of disaccharide units to their reducing ends,^{10l} the kinetic data is consistent with the proposal by Welzel and co-workers that moenomycin A mimics the growing glycan strand.⁷ Since PGTs can exist in both open and closed conformations,²³ however, moenomycin A and the growing chain may not bind to the same conformation. Efficient access to PG fragments that bind in the donor site may make it possible to obtain structures of PGTs bound to substrates.^{10p,r}

In addition to providing substrates to study PGTs, the reported synthetic route enables access to oligosaccharide fragments of PG to study the transpeptidation reaction. (i.e., peptide cross-linking). The transpeptidases are the lethal targets of the β -lactams but an inability to obtain PG oligosaccharides has precluded detailed mechanistic studies of these enzymes. The methods reported here will provide the tools necessary to understand the TPs and other penicillin-binding proteins in detail.

4. Experimental section

4.1. General methods

All reactions were carried out under an argon atmosphere with solvents dried by passage over activated alumina. Reagents were used as obtained with the following exceptions: $\text{BF}_3 \cdot \text{OEt}_2$ was distilled prior to use. Ethylenediamine was stirred over MS 4 Å for 24 h, then stored over solid KOH and distilled prior to use. TLC was carried out using SiO_2 coated glass plates (Merck, $200 \times 200 \times 0.25 \text{ mm}^3$) and spots were visualized by fluorescence quench at 254 nm or by staining with cerium ammonium sulfate or anisaldehyde solution. Flash column chromatography was performed on silica gel obtained from Sorbent Technologies (60 Å, 32–63 μm). Chromatography paper was obtained from Whatman (3 MM CHR). Analytical HPLC/MS was carried out on an Agilent Series 1100 instrument, using a Phenomenex Luna C18 3 μm column and ESI ionization. NMR spectra were recorded on a Varian I500, Varian M400, or Varian M300 spectrometer. Chemical shifts are reported in parts per million as δ and referenced to the residual internal solvent signal (CDCl_3 : 7.26 (¹H) and 77.16 (¹³C); $\text{DMSO}-d_6$: 2.50 (¹H) and 39.52 (¹³C)). High resolution mass spectrometry was performed on a Bruker microTOF instrument using ESI. Enzymes were obtained and handled as previously reported.^{10m} ¹⁴C-Heptaprenyl-lipid II was obtained as previously described.^{10c} Moenomycin A was isolated from flavomycin as reported.²⁵ Autoradiography was carried out using storage phosphor screens by GE Healthcare and a GE Healthcare Typhoon 9400 scanner.

4.2. General procedure for the Z-prenylation of allylic alcohols 14, 17, 19, and 20

The allylic alcohol was dissolved in Et_2O (1 M) and cooled to -30°C before PBr_3 (0.37 equiv) was added. MeOH and H_2O were added as TLC analysis indicated completion of the reaction. The mixture was extracted with hexane and the organic phases were washed with water, NaHCO_3 (satd) and brine, and dried over MgSO_4 . Evaporation of the solvent in vacuo provided the allylic bromide, which was used as such in the next step.

NaH (2.2 equiv) was suspended in THF (1.1 M) cooled to 0°C before ethyl acetoacetate (2.0 equiv) were added. After 15 min $n\text{-BuLi}$ (2.5 M, 2.1 equiv) was added and the mixture was stirred for 15 min before a solution of the allylic bromide (1 equiv, 2.0 M in THF) was added. After 1.5 h, Et_2O (1 \times reaction volume) and 3 M HCl

(1/2 × reaction volume) were added. The phases were separated and the organic layer was washed with H₂O and brine and dried over MgSO₄. Evaporation of the solvent in vacuo and column chromatography provided the desired ketoester.

The ketoester previously obtained (1 equiv), NEt₃ (2.0 equiv), and DMAP (0.2 equiv) were dissolved in DMPU (0.3 M in ketoester) and cooled to –30 °C. Diphenyl chlorophosphate (2.0 equiv) was added and the solution was brought to rt over 3 h. NH₄Cl (satd) and Et₂O was added, the phases were parted and the organic layer was washed with H₂O and brine and dried over MgSO₄. Removal of the solvent in vacuum and column chromatography provided the desired enol ether.

The above mentioned enol phosphate was dissolved in THF (0.06 M), NMP (9.0 equiv), and Fe(acac)₃ (0.05 equiv) were added, and the mixture was cooled to –40 °C. MeMgCl in THF (3.0 equiv) was added and the solution was stirred for 30 min before the NH₄Cl (satd) was added. The aqueous layer was extracted with Et₂O and the combined organic phases were washed with 1 M HCl, NaHCO₃ (satd) and brine and dried over MgSO₄. The solvent was evaporated in vacuo and the residue was dissolved in PhMe (0.5 M), cooled to –78 °C and treated with DIBAL-H (1.0 M in PhMe, 2.7 equiv). After 1 h MeOH was added and the mixture was brought to rt. NH₄Cl (satd), 1 M HCl, and Et₂O were added, the suspension was stirred for 1.5 h and then extracted with Et₂O. The organic phases were washed with water and brine and dried over MgSO₄. Evaporation of the solvent and column chromatography provided the desired prenylated allylic alcohol. The analytical data obtained matched the published data.²⁶

4.3. Phenyl 6-O-benzyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (27)

Acetal **25** (2.17 g, 4.44 mmol) was dissolved in CH₂Cl₂ (11.1 mL) and cooled to 0 °C. Triethylsilane (3.54 mL, 22.2 mmol) and TFA (1.70 mL, 22.2 mmol) were added and the mixture was stirred for 4 h at 0 °C. Volatile components were removed in vacuo and the residue was purified by column chromatography on SiO₂, eluting with hexane/EtOAc 1/1 to obtain the title compound **27** as colorless solid (2.04 g, 4.15 mmol, 93%).¹⁵ *R*_f (hexane/EtOAc 1/1) 0.33; δ_H (300 MHz CDCl₃) 7.83 (br, 2H), 7.73–7.70 (m, 2H), 7.39–7.26 (m, 6H), 7.22–7.19 (m, 3H), 5.60 (d, *J* 10.2 Hz, 1H), 4.60 (d, *J* 11.7 Hz, 1H), 4.56 (d, *J* 11.7 Hz, 1H), 4.36–4.30 (m, 1H), 4.23–4.16 (m, 1H), 3.85–3.75 (m, 2H), 3.70–3.55 (m, 2H), 3.35 (br, 1H), 3.00 (br, 1H); HRMS (ESI): M+Na⁺, found 514.1293; C₂₇H₂₅NO₆SNa requires 514.1295.

4.4. Phenyl 4,6-O-benzylidene-3-O-benzyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside S-oxide (26)

Acetal **25** (3.60 g, 7.40 mmol) was dissolved in DMF (37 mL) and cooled 0 °C before NaH (356 mg, 60% in mineral oil) was added. After gas evolution had ceased *n*-Bu₄NI (260 mg, 704 mmol) and BnBr (0.96 mL, 8.1 mmol) were added. After stirring the reaction at rt for 20 h, MeOH (5 mL) was added dropwise and the resulting mixture was partitioned between H₂O and CH₂Cl₂. The phases were separated and the aqueous phase was extracted three times with CH₂Cl₂. The combined organic phases were washed with 10% LiCl in water and dried over Na₂SO₄. After removal of the volatiles in vacuo the residue was purified by column chromatography on SiO₂ (hexane/EtOAc 9/1 → 8/2 → 7/3) to obtain 3-benzyloxy-**25** as colorless solid (3.01 g, 5.18 mmol, 70%).²⁷ *R*_f (hexane/EtOAc 1/1) 0.81; δ_H (300 MHz CDCl₃) 7.90–7.85 (m, 1H), 7.73–7.64 (m, 4H), 7.53–7.50 (m, 2H), 7.42–7.38 (m, 6H), 7.26–7.24 (m, 2H), 6.99–6.86 (m, 5H), 5.62 (s, 1H), 5.61 (d, *J* 10.5 Hz, 1H), 4.77 (d, *J* 12.3 Hz), 4.49 (d, *J* 12.3 Hz, 1H), 4.47–4.40 (m, 2H), 4.33–4.25 (m, 1H), 3.88–3.70 (m,

3H); HRMS (ESI): M+Na⁺, found 602.1617; C₃₄H₂₉NO₆SNa requires 602.1608.

A solution of this sulfide (3.01 g, 5.19 mmol) in CH₂Cl₂ (173 mL) was cooled to –78 °C and a solution of *m*CPBA (77% pure, as commercially available, 896 mg) in CH₂Cl₂ (104 mL) was added over 1 h. The cloudy reaction mixture was then brought to rt over 45 min and then quenched with Na₂SO₃ (10% aqueous solution). The phases were separated and the organic phase was washed with NaHCO₃ (satd) and brine and dried over Na₂SO₄. Removal of the solvent in vacuo and column chromatographic purification of the residue (SiO₂, hexane/EtOAc 6/4) gave the title compound as colorless solid and as a 1/1 mixture of diastereomers (2.72 g, 4.57 mmol, 88%). *R*_f (hexane/EtOAc 6/4) 0.25; due to formation of two sulfoxide diastereomers NMR data is not given; HRMS (ESI): M–HOSPh+Na⁺, found 492.1422; C₂₇H₂₄NO₇S requires 492.1418.

4.5. Phenyl 4,6-O-benzylidene-3-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→4)-6-O-benzyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (28)

Glycosyl acceptor **27** (1.29 g, 2.62 mmol), 4-allyl-1,2-dimethoxybenzene (1.50 mL, 8.75 mmol), and 2,6-di-*tert*-butyl-4-methylpyridine (1.08 g, 5.25 mmol) were dissolved in benzene and concentrated in vacuo to remove traces of water. The residue was dissolved in CH₂Cl₂ (65.5 mL), MS 4 Å (400 mg) was added and the suspension was stirred at rt for 45 min before it was cooled to –78 °C. After addition of Tf₂O (0.29 mL, 1.8 mmol) a solution of glycosyl donor **26** (1.04 g, 1.75 mmol) in CH₂Cl₂ (44 mL) was added over 2 h by syringe pump. After these 2 h, the solution was stirred at –60 °C for 1 h, followed by 1 h at –40 °C. The reaction was washed with NaHCO₃ (satd) and the organic phase was dried over Na₂SO₄. Removal of the solvent in vacuo, followed by column chromatography on SiO₂ (hexane/EtOAc 7/3) yielded disaccharide **28** as colorless solid (970 mg, 1.01 mmol, 58%). *R*_f (hexane/EtOAc 7/3) 0.44; δ_H (500 MHz CDCl₃) 7.89–7.82 (m, 2H), 7.74–7.68 (m, 4H), 7.51–7.48 (m, 1H), 7.49–7.39 (m, 3H), 7.32–7.26 (m, 4H), 7.19–7.15 (m, 1H), 7.12–7.08 (m, 1H), 7.06 (d, *J* 6.0 Hz, 1H), 6.96 (d, *J* 6.5 Hz, 1H), 6.00–6.84 (m, 2H), 5.58 (s, 1H), 5.47 (d, *J* 10.0 Hz, 1H), 5.31 (d, *J* 8.0 Hz, 1H), 4.75 (d, *J* 12.5 Hz, 1H), 4.48–4.44 (m, 2H), 4.40–4.34 (m, 2H), 4.23–4.16 (m, 2H), 4.08–4.00 (m, 2H), 3.79–3.64 (m, 4H), 3.50–3.47 (m, 1H), 3.26–3.20 (m, 2H); δ_C (125 MHz, CDCl₃) 168.4, 167.8, 138.3, 137.9, 137.2, 134.3, 134.2, 133.1, 132.0, 131.7, 129.4, 129.0, 128.6, 128.4, 128.3, 128.1, 127.7, 127.6, 127.6, 126.3, 124.1, 123.7, 123.5, 101.7, 100.0, 83.27, 82.7, 81.6, 78.2, 74.4, 73.1, 71.2, 68.5, 68.2, 66.3, 56.0, 55.2, 30.4; HRMS (ESI): M+Na⁺, found 983.2772; C₅₅H₄₈N₂O₁₂SNa⁺ requires 983.2820.

4.6. Phenyl 6-O-benzyl-3-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→4)-6-O-benzyl-2-deoxy-2-phthalimido-1-thio-glucopyranoside (30)

Disaccharide **28** (1.35 g, 1.40 mmol) was dissolved in CH₂Cl₂ (28.1 mL) and cooled to 0 °C. Triethylsilane (2.68 mL, 16.8 mmol) and BF₃·OEt₂ (0.36 mL, 2.8 mmol) were added and the mixture was stirred for 2 h at 0 °C. NaHCO₃ (satd) was added to the reaction mixture and the phases were parted. The organic phase was concentrated in vacuo and the residue was purified by column chromatography on SiO₂ (hexane/EtOAc 6/4 → 1/1) to obtain the title compound **30** as colorless solid (950 mg, 0.986 mmol, 70%). *R*_f (hexane/EtOAc 1/1) 0.53; δ_H (400 MHz CDCl₃) 7.92–7.80 (m, 2H), 7.74–7.70 (m, 3H), 7.58–7.55 (m, 1H), 7.35–7.34 (m, 2H), 7.31–7.28 (m, 2H), 7.23–7.22 (m, 3H), 7.17–7.15 (m, 1H), 7.11–7.05 (m, 2H), 7.00–6.97 (m, 2H), 5.49 (d, *J* 10.5 Hz, 1H), 5.30 (d, *J* 9.0 Hz, 1H), 4.69 (d, *J* 12.5 Hz, 1H), 4.45–4.42 (m, 5H), 4.33–4.20 (m, 3H), 3.97 (s, 2H), 3.75–3.62 (m, 6H), 3.55–3.50 (m, 1H), 3.25 (m, 2H); 2.62 (m, 1H); δ_C (125 MHz, CDCl₃) 168.4, 167.7, 138.3, 138.2, 138.5, 134.2, 134.2,

132.9, 132.3, 132.1, 132.0, 131.8, 128.9, 128.8, 128.6, 128.5, 128.5, 128.4, 128.1, 128.0, 127.9, 127.8, 127.6, 127.5, 123.9, 123.7, 123.5, 99.3, 83.4, 81.9, 79.0, 78.1, 74.8, 73.9, 73.8, 73.5, 73.0, 71.5, 70.1, 68.6, 55.6, 55.2; HRMS (ESI): $M+Na^+$, found 985.2900; $C_{55}H_{51}N_2O_{12}SNa^+$ requires 985.2977.

4.7. Phenyl 4,6-O-benzylidene-3-O-benzyl-2-deoxy-2-phthalimido- β -D-glucopyranosyl-(1 \rightarrow 4)-6-O-benzyl-2-deoxy-2-phthalimido-1-thio-glucopyranoside 5-oxide (29)

A solution of sulfide **28** (1.69 g, 1.76 mmol) in CH_2Cl_2 (59 mL) was cooled to $-78^\circ C$ and a solution of mCPBA (77% pure, as commercially available, 434 mg) in CH_2Cl_2 (39 mL) was added over 1 h. The cloudy reaction mixture was then brought to rt over 45 min and quenched with Na_2SO_3 (10% aqueous solution). The phases were separated and the organic phase was washed with $NaHCO_3$ (satd) and brine and dried over Na_2SO_4 . Removal of the solvent in vacuo and column chromatographic purification of the residue (SiO_2 , hexane/EtOAc 1/1) gave the title compound as colorless solid and as a 1/1 mixture of diastereomers (1.33 g, 1.36 mmol, 77%). R_f (hexane/EtOAc 6/4) 0.30; due to formation of sulfoxide diastereomers NMR spectroscopic data is not given.

4.8. Tetrasaccharide 31

Glycosyl acceptor **30** (790 mg, 0.82 mmol), 4-allyl-1,2-dimethoxybenzene (0.88 mL, 5.1 mmol), and 2,6-di-*tert*-butyl-4-methylpyridine (0.63 g, 3.1 mmol) were dissolved in benzene and concentrated in vacuo to remove traces of water. The residue was dissolved in CH_2Cl_2 (20.5 mL), MS 4 Å (150 mg) was added and the suspension was stirred at rt for 45 min before it was cooled to $-78^\circ C$. After addition of Tf_2O (0.17 mL, 1.0 mmol) a solution of glycosyl donor **29** (1.0 g, 1.0 mmol) in CH_2Cl_2 (25.5 mL) was added over 2 h by syringe pump. After these 2 h, the solution was stirred at $-60^\circ C$ for 1 h, followed by 1 h at $-40^\circ C$. The mixture was washed with $NaHCO_3$ (satd) and the organic phase was dried over Na_2SO_4 . Removal of the solvent in vacuo, followed by column chromatography on SiO_2 (hexane/EtOAc 6/4) yielded disaccharide **31** as colorless solid (818 mg, 0.451 mmol, 55%). R_f (hexane/EtOAc 6/4) 0.20; δ_H (500 MHz DMSO- D_6) 7.98–6.80 (m, 48H), 6.75–6.60 (m, 3H), 5.59 (s, 1H), 5.43 (d, J 11.0 Hz, 1H), 5.30 (d, J 9.0 Hz, 1H), 5.12 (d, J 8.5 Hz, 1H), 5.06 (d, J 7.5 Hz, 1H), 4.78 (d, J 12.5 Hz, 1H), 4.49–4.26 (m, 10H), 4.15–3.98 (m, 9H), 3.84–3.42 (m, 7H), 3.45–3.33 (m, 4H), 3.14–3.12 (m, 2H), 3.11–3.07 (m, 1H), 2.75–2.70 (m, 1H); d_C (125 MHz, DMSO- D_6) 168.8, 168.3, 168.0, 167.7, 138.5, 138.3, 138.1, 138.0, 137.7, 137.2, 134.5, 134.3, 134.2, 133.9, 132.2, 133.9, 132.7, 132.4, 132.1, 132.0, 131.8, 129.4, 128.9, 128.6, 128.5, 128.4, 128.3, 128.3, 128.0, 127.9, 127.8, 127.7, 127.6, 127.6, 127.5, 127.4, 127.4, 127.1, 126.3, 124.3, 123.9, 123.7, 123.5, 101.6, 99.9, 99.2, 96.9, 83.4, 82.8, 81.9, 81.3, 78.0, 76.5, 75.7, 74.7, 74.5, 74.4, 74.3, 74.2, 74.2, 73.1, 72.8, 72.8, 71.3, 69.6, 68.5, 68.2, 66.9, 66.2, 56.8, 56.0, 55.9, 55.2; HRMS (ESI): $M+H^+$, found 1814.5944; $C_{104}H_{93}N_4O_{24}S^+$ requires 1814.5929.

4.9. Tetraacetate 32

Tetraphthalate **31** (750 mg, 0.413 mmol) was dissolved in a mixture of THF (8.4 mL), MeCN (10.7 mL), EtOH (8.4 mL), and ethylenediamine (1.05 mL) and was stirred under an atmosphere of argon for 48 h at $60^\circ C$. Volatile components were evaporated in vacuo and the residue was dissolved in MeOH (16.8 mL) and H_2O (2.7 mL), cooled to $0^\circ C$, and 10 mL of Ac_2O were added in portions over 6 h. After evaporation of the volatiles in vacuo the residue was suspended in MeOH (50 mL). The suspension was centrifuged and the pellet dried over night in vacuo. The supernatant was concentrated in vacuo and treated as above (20 mL MeOH) to obtain the

tile compound as amorphous solid (422 mg, 289 μ mol, 70%). δ_H (500 MHz $CDCl_3$) 8.05–8.03 (m, 1H) 8.00–7.97 (m, 1H), 7.93–7.89 (m, 2H), 7.41–7.37 (m, 6H), 7.30–7.17 (m, 26H), 5.69 (s, 1H), 4.87 (d, J 12.0 Hz, 1H), 4.80 (d, J 10.5 Hz), 4.70–4.66 (m, 3H), 4.58–4.44 (m, 10H), 4.28 (d, J 12.0 Hz, 1H), 4.24–4.22 (m, 1H), 3.79–3.65 (m, 10H), 3.59–3.31 (m, 11H), 3.21–3.18 (m, 1H), 3.05–3.03 (m, 1H), 1.82 (s, 3H), 1.79 (s, 3H), 1.78 (s, 3H), 1.77 (s, 3H); d_C (125 MHz, $CDCl_3$) 169.9, 169.9, 169.8, 169.7, 139.9, 139.4, 139.4, 139.2, 139.0, 138.3, 135.7, 129.9, 129.5, 128.9, 128.9, 128.8, 128.8, 128.7, 128.6, 128.1, 128.1, 128.0, 128.0, 127.9, 127.8, 127.7, 127.7, 127.1, 126.7, 101.9, 100.8, 100.6, 86.2, 81.3, 80.9, 79.6, 79.2, 78.2, 75.8, 75.0, 74.7, 74.2, 73.9, 73.8, 72.9, 72.9, 72.8, 72.6, 69.8, 69.4, 69.2, 68.3, 66.4, 56.7, 55.5, 54.4, 39.1, 23.8, 23.7, 23.6, 23.6; HRMS (ESI): $M+H^+$, found 1461.5986; $C_{80}H_{93}N_4O_{20}S^+$ requires 1461.6098.

4.10. GlcNAc–MurNAc–GlcNAc–MurNAc derivative 33

Compound **32** (150 mg, 103 μ mol) was dissolved in DMF (5.15 mL) and cooled to $0^\circ C$. NaH (60% in mineral oil, 102 mg, ca. 25 equiv) was added and the suspension was vigorously stirred for 10 min until gas evolution had ceased. *S*-2-bromopropionic acid (93 μ L, 1.03 mmol) was added dropwise and the suspension was allowed to reach rt over 3 h before acetic acid (0.58 mL, 10 mmol) was carefully added. Volatile components were removed in vacuum over night and the residue was dissolved in benzene (1.5 mL) and MeOH (0.5 mL). This solution was cooled to $0^\circ C$ and TMS-diazomethane (2 M in hexane, 1.5 mL) was slowly added. LC/MS analysis at this point ensured that all free acid had been methylated and the reaction was quenched by addition of AcOH (0.2 mL). The mixture was concentrated in vacuum and partitioned between EtOAc and $NaHCO_3$. The organic phase was dried over Na_2SO_4 , concentrated in vacuum, and the residue was purified by column chromatography (SiO_2 , CH_2Cl_2 /MeOH 96/4) to obtain the title compound as colorless solid (126 mg, 77 μ mol, 75%). R_f (CH_2Cl_2 /MeOH 96/4) 0.33; δ_H (500 MHz $CDCl_3$) 7.60–7.59 (d, 1H), 7.52–7.14 (m, 34H), 5.58 (s, 1H), 4.88 (d, J 12.5 Hz, 1H), 4.79 (d, J 11.5 Hz, 2H), 4.73–4.57 (m, 4H), 4.57–4.34 (m, 10H), 4.26–4.23 (m, 2H), 4.18 (br, 1H), 4.05–3.99 (m, 2H), 3.89 (m, 1H), 3.78–3.41 (m, 18H), 3.77 (s, 3H), 3.70 (s, 3H), 3.35–3.30 (m, 1H), 3.30–3.25 (m, 1H), 3.25–3.20 (m, 1H), 2.04 (s, 3H), 1.97 (s, 3H), 1.96 (s, 3H), 1.73 (s, 3H), 1.32 (d, J 7.5 Hz, 3H), 1.18 (d, J 7.0 Hz, 3H); d_C (125 MHz, $CDCl_3$) 176.6, 176.4, 172.7, 172.0, 170.7, 169.9, 162.8, 139.0, 138.6, 138.6, 138.5, 138.0, 137.4, 135.9, 130.7, 129.4, 129.4, 129.0, 129.0, 128.8, 128.7, 128.6, 128.3, 128.2, 128.1, 128.0, 127.8, 127.8, 127.6, 126.9, 126.2, 101.7, 101.5, 100.7, 100.3, 88.8, 82.8, 82.8, 80.4, 79.6, 79.5, 78.1, 77.0, 76.7, 75.0, 74.6, 74.2, 73.9, 73.7, 73.4, 72.0, 71.9, 70.1, 69.3, 69.0, 67.3, 66.0, 55.8, 55.2, 53.8, 52.5, 52.4, 52.2, 36.7, 31.7, 23.9, 23.6, 23.6, 23.2, 19.0, 18.8; HRMS (ESI): $M+H^+$, found 1633.6852; $C_{88}H_{105}N_4O_{24}S^+$ requires 1633.6834.

4.11. Determination of the IC_{50} of moenomycin A

Solutions of PBP1a (*E. coli*, 20 nM) in 50 mM HEPES pH 7.5, 10 mM $CaCl_2$, 1000 units/mL penicillin G, and 20% DMSO (v/v) were incubated for 20 min with solutions of moenomycin A of different concentrations. In the pre-incubation experiments the PBP1a solutions were first incubated with Gal-lipid IV (1.36 μ M) for 20 min. Reactions were initiated by addition of ^{14}C -lipid II (4 μ M, $^3H/^{14}C$ 1/3) and were quenched after 20 min (MmA only) and 45 min (+LPIV) with an equal volume of 10% Triton X-100 solution on ice. The mixtures obtained were separated by paper strip chromatography (isobutyric acid/1 M NH_4OH 5/3). The paper strips were cut to obtain the top 4/5 (containing monomer) and the lower 1/5 (containing PG). These parts were immersed in EcoLite(+) scintillation cocktail (MP Biomedical) and analyzed by an LS 6500 scintillation counter (Beckman Coulter). The normalized activity (A) was

calculated relative to a control reaction (no MmA, no LPIV) and plotted as a function of $\log(c(\text{MmA}))$. The IC_{50} value was extracted with OriginPro 7.0.

4.12. SDS-page assay

Solutions of the enzymes (0.24 μM or 0.48 μM) in 50 mM HEPES pH 7.5, 10 mM CaCl_2 , 1000 units/mL penicillin G were treated with solutions of MmA in different concentrations for 20 min. The reaction was initiated by addition of ^{14}C -lipid II (8 μM , $^{14}\text{C}/^{13}\text{C}$ 3/1) and quenched after 20 min by heat (90 °C, 5 min). The volatiles were removed by vacuum centrifugation and the residue was taken up in buffer (15% SDS, Lämmli 6X) and analyzed by SDS-PAGE.²⁴

Acknowledgements

Dr. Tania Lupoli and Dr. Matthew Lebar are acknowledged for their help with the biochemical experiments. This research was supported by the National Institutes of Health (GM076710 and GM066174) and by the German Academic Exchange Service (DAAD; postdoctoral fellowship to C.M.G.).

Supplementary data

NMR spectra of new compounds. Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.tet.2011.09.114.

References and notes

- Holtje, J. V. *Microbiol. Mol. Biol. Rev.* **1998**, *62*, 181.
- Vollmer, W.; Bertsche, U. *Biochim. Biophys. Acta* **2008**, *1778*, 1714.
- (a) Arias, C. A.; Murray, B. E. *N. Engl. J. Med.* **2009**, *360*, 439; (b) Cohen, M. L. *Nature* **2000**, *406*, 762.
- Kahne, D.; Leimkuhler, C.; Lu, W.; Walsh, C. *Chem. Rev.* **2005**, *105*, 425.
- Walker, S.; Chen, L.; Hu, Y.; Rew, Y.; Shin, D.; Boger, D. L. *Chem. Rev.* **2005**, *105*, 449.
- Fisher, J. F.; Meroueh, S. O.; Mobashery, S. *Chem. Rev.* **2005**, *105*, 395.
- Welzel, P. *Chem. Rev.* **2005**, *105*, 4610.
- (a) Halliday, J.; McKeveney, D.; Muldoon, C.; Rajaratnam, P.; Meutermans, W. *Biochem. Pharmacol.* **2006**, *71*, 957; (b) Ostash, B.; Walker, S. *Curr. Opin. Chem. Biol.* **2005**, *9*, 459; (c) Wright, G. D. *Science* **2007**, *315*, 1373; (d) Goldman, R. C.; Gange, D. *Curr. Med. Chem.* **2000**, *7*, 801.
- (a) Butaye, P.; Beviere, L. A.; Haesebrouck, F. *Antimicrob. Agents Chemother.* **2001**, *45*, 1374; (b) Hentschel, S.; Kusch, D.; Sinell, H.-J. *Zentralblatt für Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene, I. Abteilung, Originale, Reihe B: Hygiene, Betriebshygiene, präventive Medizin* 1979, *168*, 546.
- (a) Men, H.; Park, P.; Ge, M.; Walker, S. *J. Am. Chem. Soc.* **1998**, *120*, 2484; (b) Breukink, E.; Wiedemann, I.; van Kraaij, C.; Kuipers, O. P.; Sahl, H.-G.; de Kruijff, B. *Science* **1999**, *286*, 2361; (c) Ye, X. Y.; Lo, M. C.; Brunner, L.; Walker, D.; Kahne, D.; Walker, S. *J. Am. Chem. Soc.* **2001**, *123*, 3155; (d) Schwartz, B.; Markwalder, J. A.; Wang, Y. *J. Am. Chem. Soc.* **2001**, *123*, 11638; (e) Lazar, K.; Walker, S. *Curr. Opin. Chem. Biol.* **2002**, *6*, 786; (f) VanNieuwenhze, M. S.; Mauldin, S. C.; Zia-Ebrahimi, M.; Winger, B. E.; Hornback, W. J.; Saha, S. L.; Aikins, J. A.; Blaszcak, L. C. *J. Am. Chem. Soc.* **2002**, *124*, 3656; (g) Breukink, E.; van Heusden, H. E.; Vollmerhaus, P. J.; Swiezewska, E.; Brunner, L.; Walker, S.; Heck, A. J.; de Kruijff, B. *J. Biol. Chem.* **2003**, *278*, 19898; (h) Chen, L.; Walker, D.; Sun, B.; Hu, Y.; Walker, S.; Kahne, D. *Proc. Natl. Acad. Sci. U.S.A.* **2003**, *100*, 5658; (i) Hu, Y.; Helm, J. S.; Chen, L.; Ye, X. Y.; Walker, S. *J. Am. Chem. Soc.* **2003**, *125*, 8736; (j) Chen, L.; Yuan, Y.; Helm, J. S.; Hu, Y.; Rew, Y.; Shin, D.; Boger, D. L.; Walker, S. *J. Am. Chem. Soc.* **2004**, *126*, 7462; (k) Breukink, E.; de Kruijff, B. *Nat. Rev. Drug Discovery* **2006**, *5*, 321; (l) Perlstein, D. L.; Zhang, Y.; Wang, T. S.; Kahne, D. E.; Walker, S. *J. Am. Chem. Soc.* **2007**, *129*, 12674; (m) Zhang, Y.; Fechter, E. J.; Wang, T.-S. A.; Barrett, D.; Walker, S.; Kahne, D. E. *J. Am. Chem. Soc.* **2007**, *129*, 3080; (n) Vollmer, W.; Blanot, D.; de Pedro, M. A. *FEMS Microbiol. Rev.* **2008**, *32*, 149; (o) Lupoli, T. J.; Taniguchi, T.; Wang, T.-S.; Perlstein, D. L.; Walker, S.; Kahne, D. E. *J. Am. Chem. Soc.* **2009**, *131*, 18230; (p) Perlstein, D. L.; Wang, A.T.-S.; Doud, E. H.; Kahne, D.; Walker, S. *J. Am. Chem. Soc.* **2010**, *132*, 48; (q) Lupoli, T. J.; Tsukamoto, H.; Doud, E. H.; Wang, T.-S. A.; Walker, S.; Kahne, D. *J. Am. Chem. Soc.* **2011**, *133*, 10748; (r) Wang, T.-S. A.; Lupoli, T. J.; Sumida, Y.; Tsukamoto, H.; Wu, Y.; Rebets, Y.; Kahne, D.; Walker, S. *J. Am. Chem. Soc.* **2011**, *133*, 8528; (s) Shih, H.-W.; Chen, K.-T.; Cheng, T.-J. R.; Wong, C.-H.; Cheng, W.-C. *Org. Lett.* **2011**, *13*, 5306.
- (a) Casey, C. P.; Marten, D. F. *Synth. Commun.* **1973**, *3*, 321; (b) Casey, C. P.; Marten, D. F.; Boggs, R. A. *Tetrahedron Lett.* **1973**, 2071; (c) Casey, C. P.; Marten, D. F. *Tetrahedron Lett.* **1974**, 925.
- (a) Sum, F.-W.; Weiler, L. *Can. J. Chem.* **1979**, *57*, 1431; (b) Alderdice, M.; Spino, C.; Weiler, L. *Tetrahedron Lett.* **1984**, *25*, 1643.
- Hayashi, N.; Nakada, M. *Tetrahedron Lett.* **2009**, *50*, 232.
- Tsukamoto, H.; Kahne, D. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 5050.
- Jain, R. K.; Matta, K. L. *Carbohydr. Res.* **1992**, *226*, 91.
- Averso, M. C.; Barattucci, A.; Bonaccorsi, P. *Tetrahedron* **2008**, *64*, 7659.
- (a) Kahne, D.; Walker, S.; Cheng, Y.; Van Engen, D. J. *Am. Chem. Soc.* **1989**, *111*, 6881; (b) Gildersleeve, J.; Pascal, R. A., Jr.; Kahne, D. J. *Am. Chem. Soc.* **1998**, *120*, 5961; (c) Gildersleeve, J.; Smith, A.; Sakurai, K.; Raghavan, S.; Kahne, D. J. *Am. Chem. Soc.* **1999**, *121*, 6176.
- Debenham, J.; Rodebaugh, R.; Fraser-Reid, B. *Liebigs Ann.* **1997**, 791.
- For a recent study, see: Ohlin, M.; Johnsson, R.; Ellervik, U. *Carbohydr. Res.* **2011**, *346*, 1358.
- See [Supplementary data](#) for details.
- Galactose-lipid IV (Gal-lipid IV) was used since lipid IV itself was found to be polymerized by GTs. See Ref. [100](#), p.r.
- Polymerization reactions were run for 45 and 20 min with and without lipid IV, respectively, which leads to maximum conversion in both cases in the absence of moenomycin see Ref. [10](#).
- (a) Lovering, A. L.; de Castro, L. H.; Lim, D.; Strynadka, N. C. *J. Science* **2007**, *315*, 1402; (b) Yuan, Y. Q.; Barrett, D.; Zhang, Y.; Kahne, D.; Sliz, P.; Walker, S. *Proc. Natl. Acad. Sci. U.S.A.* **2007**, *104*, 5348; (c) Yuan, Y. Q.; Fuse, S.; Ostash, B.; Sliz, P.; Kahne, D.; Walker, S. *ACS Chem. Biol.* **2008**, *3*, 429; (d) Lovering, A. L.; Gretes, M.; Strynadka, N. C. *Curr. Opin. Struct. Biol.* **2008**, *18*, 534; (e) Heaslet, H.; Shaw, B.; Mistry, A.; Miller, A. A. *J. Struct. Biol.* **2009**, *167*, 129; (f) Sung, M. T.; Lai, Y. T.; Huang, C. Y.; Chou, L. Y.; Shih, H. W.; Cheng, W. C.; Wong, C. H.; Ma, C. *Proc. Natl. Acad. Sci. U.S.A.* **2009**, *106*, 8824.
- Barrett, D.; Wang, T. S.; Yuan, Y.; Zhang, Y.; Kahne, D.; Walker, S. *J. Biol. Chem.* **2007**, *282*, 31964.
- Adachi, M.; Zhang, Y.; Leimkuhler, C.; Sun, B.; LaTour, J. V.; Kahne, D. E. *J. Am. Chem. Soc.* **2006**, *128*, 14012.
- (a) Brown, R. C. D.; Bataille, C. J.; Hughes, R. M.; Kenney, A.; Luker, T. J. *J. Org. Chem.* **2002**, *67*, 8079; (b) Yu, J. S.; Kleckley, T. S.; Wiemer, D. F. *Org. Lett.* **2005**, *7*, 4803; (c) Danilov, L. L.; Druzhinia, T. N.; Kalinchuk, N. A.; Maltsev, S. D.; Shibaev, V. N. *Chem. Phys. Lipids* **1989**, *51*, 191.
- Chiara, J. L.; García, Á.; Cristóbal-Lumbroso, G. *J. Org. Chem.* **2005**, *70*, 4143.